Explore the Agenda
9:00 am Registration & Morning Coffee
Morning Session
9:30 am Optimizing Donor Variability, Cryopreservation, Bioreactors & Scalability to Build Reliable Manufacturing Processes for Clinical Success
Advancing cell and gene therapies from preclinical to clinical stages requires tackling critical manufacturing hurdles. Donor variability, cryopreservation, scalability, and equipment choices, including the use of bioreactors, all impact product quality, reproducibility, and regulatory readiness. This workshop explores practical strategies to strengthen manufacturing systems, mitigate risk, and ensure a smooth transition into the clinic.
Join this workshop to:
- Understand how donor variability and cryopreservation affect product quality, and ways to reduce these risks
- Explore scalability, bioreactor implementation, and equipment decisions that drive consistency and compliance
- Review case-based approaches for moving from preclinical data to robust clinical programs
12:30 pm Lunch Break & Networking
Afternoon Session
1:30 pm Harnessing Biomarker Discovery & Translational Tools to Accelerate NK Therapy Clinical Success
Advancing NK-based therapies from preclinical proof-of-concept to meaningful clinical outcomes depends on identifying the right patients and monitoring their responses effectively. Predictive biomarkers, translational analytics, and innovative assay platforms are critical to reduce trial risk, guide dosing, and validate therapeutic mechanisms. This workshop explores state-of-the-art strategies to integrate biomarker discovery and translational science into NK therapy development to de-risk programs and speed regulatory and clinical milestones.
Join this workshop to:
- Understand emerging biomarkers for patient selection, persistence, and therapeutic response in autoimmunity and oncology
- Explore cutting-edge analytical tools, single-cell sequencing, spatial transcriptomics, and functional NK assays to uncover actionable insights
- Review case-based examples of how translational strategies can refine trial design, optimize dosing, and improve go/no-go decisions